Sign in

    Rohan Walcott • Stifel, Nicolaus & Company

    Rohan Walcott's questions to MaxCyte Inc (MXCT) leadership

    Rohan Walcott's questions to MaxCyte Inc (MXCT) leadership • Q2 2025

    Question

    Rohan Walcott, on for Dan Arias, asked for guidance on the quarterly revenue cadence for the second half of 2025 and sought more details on the strong instrument sales, including customer sentiment and performance expectations for the remainder of the year.

    Answer

    CFO Douglas Swirsky stated that revenue is expected to be slightly weighted towards Q4, but not materially. President and CEO Maher Masoud attributed the 22% year-over-year growth in instrument revenue to a strategy of seeding the market with lower-priced systems and noted that capital expenditure headwinds are beginning to dissipate. Swirsky added that ex-US sales, particularly in Asia Pacific, have been a source of strength.

    Ask Fintool Equity Research AI

    Rohan Walcott's questions to MaxCyte Inc (MXCT) leadership • Q3 2024

    Question

    Rohan Walcott, on for Dan Arias, inquired about the typical duration for signing an SPL agreement and whether company size is a factor. He also asked for an update on beta customer feedback for the VLX platform.

    Answer

    CEO Maher Masoud explained that the SPL signing timeline, typically 12-18 months, is driven by the scientific partnership and development process, not the size of the company. Regarding the VLX platform, Masoud stated that the company is still working with and learning from early adopters in a methodical way and declined to comment further on specific feedback at this time.

    Ask Fintool Equity Research AI